- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00130117
Study of Leptin for the Treatment of Hypothalamic Amenorrhea
Randomized, Double-blind, Placebo-controlled Trial of Human Recombinant Leptin (r-metHuLeptin) for the Treatment of Hypothalamic (Exercise-Induced) Amenorrhea
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Leptin is a hormone secreted by fat cells under normal conditions and acts in the brain to regulate energy usage and hormone levels. Women with HA who do not have regular periods have low leptin levels and may also have other hormone abnormalities as well as loss of bone density (osteopenia or osteoporosis). This study will evaluate how leptin (a fat cell hormone that normally circulates in the blood) affects bone density, menstrual periods, hormone levels, bone metabolism (how bone forms and turns over), immune function (how well the body can fight infection), metabolic rate (how many calories are used at rest), and overall sense of well-being and appetite in women with HA (i.e. no regular menstrual periods due to low levels of pituitary hormones that regulate estrogen production from the ovary). It will also investigate whether leptin replacement can be used as an adjunct to the current standard of care for HA patients, i.e. OCPs.
Part A is a Randomized, placebo-controlled 36-week study. Part B is an Optional open-label 52-week study. There will also be an optional Reward Sub-study, including healthy controls, designed to investigate leptin's relation to reward processing by collecting participants' brain and behavioral responses to images (e.g., pictures of food vs. non-food). Brain responses will be collected and will also be assessed via functional Magnetic Resonance Imaging (fMRI).
Comparison: Part A = leptin-treated group to placebo-treated group and Part B optional sub study = leptin-treated group to health controls
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Beth Israel Deaconess Medical Center General Clinical Research Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria for HA subjects
- Hypothalamic amenorrhea of at least 6 months duration with low or normal LH and FSH, e.g. due to strenuous exercise (running >20 miles per week or equivalent) or low weight
- Can be secondary HA OR primary HA with some pubertal development and normal screening labs
- Age 18-35 years old
- Body weight within +/- 15% of ideal body weight and stable for 6 months (no change > 5 lbs)
- Baseline leptin <5 ng/mL (except for the Cognitive Sub-Study Baseline visit where baseline leptin will be greater than 5ng/mL)
Inclusion criteria for eumenorrheic controls for Reward Sub-study
- Normal menstrual cycles (between 25 and 35 days)
- Age 18-35
- Body weight within +/- 15% of ideal body weight and stable 6 months (no change > 5 lbs)
- Baseline leptin >5 ng/mL
Exclusion criteria:
- We will exclude subjects with:
- Significant medical history that may affect the concentrations of the hormones to studied or ability to participate in the study
- renal or hepatic disease (creatinine > 1.4, AST/ALT > 2x upper limit of normal)
- diagnosed diabetes mellitus
- myocardial ischemia
- malignancy (other than basal cell carcinoma of the skin or in situ carcinoma of the cervix)
- malabsorption
- alcoholism, drug abuse, or smoking
- active eating disorder
- depression or other psychiatric disease
- anemia (Hb10 gm/dL on 2 occasions)
- Conditions that are contraindicated for oral contraceptive use:
- Thrombophlebitis or thromboembolic disorders
- A past history of deep vein thrombophlebitis or thromboembolic disorders
- Cerebral vascular or coronary artery disease
- Known or suspected carcinoma of the breast
- Carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia
- Undiagnosed abnormal genital bleeding
- Hepatic adenomas or carcinomas
- Cholestatic jaundice of pregnancy or jaundice with prior OCP use
- Other endocrine causes of amenorrhea, e.g.
- hyperprolactinemia
- hypothyroidism or hyperthyroidism
- Cushing's syndrome
- congenital adrenal hyperplasia (elevated 17 OH progesterone)
- polycystic ovarian syndrome (elevated androgens or LH/FSH ratio >1.5)
- primary ovarian failure (elevated FSH)
- On medications known to affect the hormones to be measured such as
- glucocorticoids
- anti seizure medications
- thyroid hormones
- estrogen (must be off at least 3 months prior to participating in the study)
- A known history of anaphylaxis or anaphylactoid-like reactions, or a known hypersensitivity to E. Coli derived proteins
- Breast feeding, pregnant, or wanting to become pregnant during the next 6 months.
- We will screen for these conditions through a detailed history and systems review, physical examination, laboratory evaluation (as described above in Screening Methods), and EKG.
- In the Reward Sub-study subjects will be asked to fill out a standard BIDMC MRI safety screening form prior to entering the magnet.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: r-metHuLeptin
r-metHuLeptin administered subcutaneously.
|
Starting dose: 0.08mg/kg once daily Subcutaneous injection.
Other Names:
Sprintec taken orally once daily.
Other Names:
|
Placebo Comparator: Oral Contraceptive Pills (OCPs)
PLACEBO
|
Sprintec taken orally once daily.
Other Names:
placebo (no active medication)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
the Difference Between the Placebo and Leptin Treated Groups in the Change in Bone Mineral Content(BMC) at the Anteroposterior (AP) Spine From Baseline to 36 Weeks
Time Frame: 36 weeks
|
36 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Bone Markers - Ctx and Sclerostin
Time Frame: 36 weeks
|
36 weeks
|
Body Composition BMI
Time Frame: 36 weeks
|
36 weeks
|
Total Body BMD
Time Frame: 36 weeks
|
36 weeks
|
Body Fat
Time Frame: 36 weeks
|
36 weeks
|
Total Body BMD
Time Frame: 9 months
|
9 months
|
Lumbar BMD
Time Frame: 9 months
|
9 months
|
Radial BMD
Time Frame: 9 months
|
9 months
|
Hip BMD
Time Frame: 9months
|
9months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Christos S Mantzoros, MD, ScD, Beth Israel Deaconess Medical Center, Harvard Medical School
Publications and helpful links
General Publications
- Welt CK, Chan JL, Bullen J, Murphy R, Smith P, DePaoli AM, Karalis A, Mantzoros CS. Recombinant human leptin in women with hypothalamic amenorrhea. N Engl J Med. 2004 Sep 2;351(10):987-97. doi: 10.1056/NEJMoa040388.
- Mantzoros CS, Magkos F, Brinkoetter M, Sienkiewicz E, Dardeno TA, Kim SY, Hamnvik OP, Koniaris A. Leptin in human physiology and pathophysiology. Am J Physiol Endocrinol Metab. 2011 Oct;301(4):E567-84. doi: 10.1152/ajpendo.00315.2011. Epub 2011 Jul 26.
- Sienkiewicz E, Magkos F, Aronis KN, Brinkoetter M, Chamberland JP, Chou S, Arampatzi KM, Gao C, Koniaris A, Mantzoros CS. Long-term metreleptin treatment increases bone mineral density and content at the lumbar spine of lean hypoleptinemic women. Metabolism. 2011 Sep;60(9):1211-21. doi: 10.1016/j.metabol.2011.05.016. Epub 2011 Jul 7.
- Chou SH, Chamberland JP, Liu X, Matarese G, Gao C, Stefanakis R, Brinkoetter MT, Gong H, Arampatzi K, Mantzoros CS. Leptin is an effective treatment for hypothalamic amenorrhea. Proc Natl Acad Sci U S A. 2011 Apr 19;108(16):6585-90. doi: 10.1073/pnas.1015674108. Epub 2011 Apr 4.
- Chrysafi P, Perakakis N, Farr OM, Stefanakis K, Peradze N, Sala-Vila A, Mantzoros CS. Leptin alters energy intake and fat mass but not energy expenditure in lean subjects. Nat Commun. 2020 Oct 13;11(1):5145. doi: 10.1038/s41467-020-18885-9.
- Bouzoni E, Perakakis N, Mantzoros CS. Circulating profile of Activin-Follistatin-Inhibin Axis in women with hypothalamic amenorrhea in response to leptin treatment. Metabolism. 2020 Dec;113:154392. doi: 10.1016/j.metabol.2020.154392. Epub 2020 Oct 10.
- Foo JP, Polyzos SA, Anastasilakis AD, Chou S, Mantzoros CS. The effect of leptin replacement on parathyroid hormone, RANKL-osteoprotegerin axis, and Wnt inhibitors in young women with hypothalamic amenorrhea. J Clin Endocrinol Metab. 2014 Nov;99(11):E2252-8. doi: 10.1210/jc.2014-2491. Epub 2014 Aug 22.
- Hwang JJ, Thakkar B, Chamberland JP, Mantzoros CS. Circulating fetuin-A levels are not affected by short and long-term energy deprivation and/or by leptin administration. Metabolism. 2014 Jun;63(6):754-9. doi: 10.1016/j.metabol.2014.02.006. Epub 2014 Feb 17.
- Matarese G, La Rocca C, Moon HS, Huh JY, Brinkoetter MT, Chou S, Perna F, Greco D, Kilim HP, Gao C, Arampatzi K, Wang Z, Mantzoros CS. Selective capacity of metreleptin administration to reconstitute CD4+ T-cell number in females with acquired hypoleptinemia. Proc Natl Acad Sci U S A. 2013 Feb 26;110(9):E818-27. doi: 10.1073/pnas.1214554110. Epub 2013 Feb 4.
- Aronis KN, Diakopoulos KN, Fiorenza CG, Chamberland JP, Mantzoros CS. Leptin administered in physiological or pharmacological doses does not regulate circulating angiogenesis factors in humans. Diabetologia. 2011 Sep;54(9):2358-67. doi: 10.1007/s00125-011-2201-x. Epub 2011 Jun 10.
- Alonso-Alonso M, Ziemke F, Magkos F, Barrios FA, Brinkoetter M, Boyd I, Rifkin-Graboi A, Yannakoulia M, Rojas R, Pascual-Leone A, Mantzoros CS. Brain responses to food images during the early and late follicular phase of the menstrual cycle in healthy young women: relation to fasting and feeding. Am J Clin Nutr. 2011 Aug;94(2):377-84. doi: 10.3945/ajcn.110.010736. Epub 2011 May 18.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2004P000123
- 1R34HD048526-01 (U.S. NIH Grant/Contract)
- 5M01RR001032-32 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Amenorrhea
-
Mayo ClinicEunice Kennedy Shriver National Institute of Child Health and Human Development...RecruitingHypothalamic AmenorrheaUnited States
-
University of Colorado, Colorado SpringsRecruitingAmenorrhea SecondaryUnited States
-
University of California, DavisCompletedBreast Feeding | Milk Expression, Breast | Amenorrhea, PostpartumUnited States
-
Imperial College LondonUniversity College, LondonRecruiting
-
TherapeuticsMDTerminated
-
Solvay PharmaceuticalsCompletedSecondary AmenorrheaUnited States
-
Catholic University of the Sacred HeartUnknownHypothalamic AmenorrheaItaly
-
Massachusetts General HospitalEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedExercise-related AmenorrheaUnited States
-
University Hospital, LilleRecruitingChemotherapy-Induced AmenorrheaFrance
-
Fondazione Policlinico Universitario Agostino Gemelli...Recruiting
Clinical Trials on r-metHuLeptin
-
Beth Israel Deaconess Medical CenterAmgenCompletedEnergy Deficiency Due to Short-term FastingUnited States
-
Beth Israel Deaconess Medical CenterNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); A... and other collaboratorsCompleted
-
University of MiamiNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed
-
University of MiamiNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed
-
Beth Israel Deaconess Medical CenterNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); A...CompletedHAART-induced Lipodystrophy and Metabolic SyndromeUnited States
-
Rockefeller UniversityColumbia University; Weill Medical College of Cornell University; St. Luke's-Roosevelt...Completed
-
University of Texas Southwestern Medical CenterCompletedInsulin Resistance | Partial Lipodystrophy | Generalized Lipodystrophy | HypoleptinemiaUnited States
-
University of California, Los AngelesUniversity of Colorado, Denver; National Institute of Allergy and Infectious... and other collaboratorsCompletedRNA Virus Infections | Respiratory Tract Infections | Influenza, Human | Orthomyxoviridae Infections | Respiratory Tract Disease | Virus Disease | Physiological Effects of Drugs | VaccinesUnited States
-
Klinikum NürnbergUnknown
-
University of California, Los AngelesNational Institute of Allergy and Infectious Diseases (NIAID)CompletedRespiratory Tract Infections | Influenza | VaccinesUnited States